NEWS
-
PRESS RELEASE
Metcela raises 520 million yen in Series A financing round
With this financing, Metcela has now raised a total of 920 Million yen including the previous investments and grants
Metcela, a biotech startup specializing in fibroblast-based cell therapy for heart failure treatment, announced the successful closing of its 520 million yen ($4.6 million) Series A round. The round was led by Beyond Next Ventures, with additional participation from new investors, Eight Road Ventures Japan, F-Prime Capital Partners, Japan Lifeline Co., Ltd., Sony Innovation Fund, The Dai-ichi Life Insurance Company, Limited, and KSP Inc. With this financing, Metcela has raised a total sum of 920 million yen ($8.2 million), including previously raised investments and grants.
-
NEWS
Nikkei: Metcela confirmed the therapeutic effect on the heart failure medicine
Nikkei Shinbun wrote an article on Metcela on 18th September 2017 (Japanese).
https://www.nikkei.com/article/DGKKZO21214120V10C17A9TJE000/